Below we share a summary of a recent piece published on Anthem.com, Pharmacy Coverage for Gene Therapies & Financial Risk.
Gene therapy is rapidly reshaping the future of healthcare. As of mid-2025, the FDA has approved more than 30 cell and gene therapies in the U.S., with projections of up to 200 additional approvals anticipated by 2030. This expanding pipeline offers transformative potential for millions of patients with rare and complex conditions. Today, strategizing to manage both the impact and the cost of gene therapies is a topic on many employers’ minds.
For employers, Anthem’s Gene Therapy Solution provides protection against financial risk through stop-loss coverage while delivering comprehensive care management for employees and their families. The approach combines medical and pharmacy benefits and outcome-based agreements to balance innovation with affordability.
CarelonRx, Anthem’s pharmacy benefit manager, closely evaluates new therapies to ensure treatments are medically necessary and cost-effective. By aligning coverage strategies with evolving therapies, employers can connect their workforce to life-changing care while safeguarding organizational resources.
Read the full article here:
Pharmacy Coverage For Gene Therapies & Financial Risk | Anthem
You may also be interested in:
Enhancing health outcomes through community pharmacy care
From pipeline to prescription: the formulary development process at CarelonRx